Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;23(4):320-6.
doi: 10.1097/qco.0b013e3283398dc1.

Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact

Jesús Oteo  1 , María Pérez-Vázquez, José Campos
Affiliations
Review

Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact

Jesús Oteo et al. Curr Opin Infect Dis. 2010 Aug.

Abstract

Purpose of review: This review discusses the recent findings (July 2008-January 2010) on extended-spectrum [beta]-lactamase (ESBL)-producing Escherichia coli, mainly focussed on the epidemiology and clinical impact of infections owing to this pathogen.

Recent findings: CTX-M-producing E. coli, mainly the CTX-M-15 producers, has emerged and disseminated worldwide as an important cause of both nosocomial and community-onset infections. The clonal spread of the ST131 epidemic E. coli strain is linked not only to the CTX-M-15 pandemia but also to other ESBLs types. The most commonly reported risk factors for community-onset ESBL-producing E. coli infections are contact with healthcare centres, recent use of antimicrobial agents, and presence of comorbidities. But infections owing to ESBL-producing E. coli in patients without obvious risk factors can occur, probably related to the increase of healthy carriers colonized with this pathogen. The main significant predictor of mortality caused by ESBL-producing E. coli is inadequate initial antimicrobial therapy. Alternatives of treatment of severe ESBL-producing E. coli infections included carbapenems, amikacin, tigecycline, and [beta]-lactam/[beta]-lactamase inhibitor combinations; with some of them enough clinical evidence is lacking (tigecycline, [beta]-lactam/[beta]-lactamase inhibitor combinations). For urinary tract infections, fosfomycin and nitrofurantoin could be useful.

Summary: The worldwide emergence of multiresistant ESBL-producing E. coli raises key therapeutic problems; interventions addressed to their quick detection and early appropriate antibiotic treatment and prevention are urgently needed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types